RU2151612C1 - Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека - Google Patents

Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека Download PDF

Info

Publication number
RU2151612C1
RU2151612C1 RU95115405/14A RU95115405A RU2151612C1 RU 2151612 C1 RU2151612 C1 RU 2151612C1 RU 95115405/14 A RU95115405/14 A RU 95115405/14A RU 95115405 A RU95115405 A RU 95115405A RU 2151612 C1 RU2151612 C1 RU 2151612C1
Authority
RU
Russia
Prior art keywords
immunoglobulin
human
humanized
antibody
dreg
Prior art date
Application number
RU95115405/14A
Other languages
English (en)
Russian (ru)
Other versions
RU95115405A (ru
Inventor
Ман Сунг Ко (GB)
Ман Сунг КО
Original Assignee
Протеин Дизайн Лэбс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протеин Дизайн Лэбс, Инк. filed Critical Протеин Дизайн Лэбс, Инк.
Publication of RU95115405A publication Critical patent/RU95115405A/ru
Application granted granted Critical
Publication of RU2151612C1 publication Critical patent/RU2151612C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU95115405/14A 1992-12-01 1993-11-30 Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека RU2151612C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98394692A 1992-12-01 1992-12-01
US07/983.946 1992-12-01
US07/983,946 1992-12-01

Publications (2)

Publication Number Publication Date
RU95115405A RU95115405A (ru) 1998-01-10
RU2151612C1 true RU2151612C1 (ru) 2000-06-27

Family

ID=25530200

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95115405/14A RU2151612C1 (ru) 1992-12-01 1993-11-30 Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека

Country Status (12)

Country Link
EP (1) EP0671951A4 (fr)
JP (1) JPH08503617A (fr)
KR (1) KR100371784B1 (fr)
AU (1) AU689090B2 (fr)
CA (1) CA2149025A1 (fr)
CZ (1) CZ140195A3 (fr)
FI (1) FI952658A0 (fr)
HU (1) HUT71790A (fr)
NO (1) NO952160L (fr)
PL (1) PL309249A1 (fr)
RU (1) RU2151612C1 (fr)
WO (1) WO1994012215A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482131C2 (ru) * 2004-05-10 2013-05-20 Эбдженомикс Кооператиф У.А. Антитела
RU2580017C2 (ru) * 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
RU2582261C2 (ru) * 2011-02-25 2016-04-20 Редженерон Фармасьютикалс, Инк. Мыши adam6
RU2603097C2 (ru) * 2010-12-21 2016-11-20 Селексис Фармасьютикалс Корпорейшн Антитела к р-селектину и способы их применения и идентификации
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US11666040B2 (en) 2012-06-12 2023-06-06 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RU2805176C1 (ru) * 2020-01-24 2023-10-11 Пфайзер Инк. Антитела против e-селектина, композиции и способы применения

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
WO1996040942A1 (fr) * 1995-06-07 1996-12-19 Cytel Corporation Anticorps humanises anti-e-selectine
AU746888B2 (en) * 1995-08-17 2002-05-02 Protein Design Labs, Inc. Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
CZ45498A3 (cs) * 1995-08-17 1999-01-13 Protein Design Labs, Inc. Použití antiselektinových protilátek pro výrobu farmaceutických kompozic určených pro prevenci mnohačetného selhání orgánů v důsledku vícečetného úrazu a pro prevenci akutního poškození orgánů po aplikaci mimotělního krevního objehu
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
ATE358492T1 (de) * 1996-09-27 2007-04-15 Univ Columbia Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
WO1999043353A2 (fr) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Therapie combinee par anti-selectine et immunodepresseur
US20020029391A1 (en) * 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (fr) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
MX2010006097A (es) 2007-12-05 2010-08-04 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para tratar el prurito.
RU2531521C2 (ru) 2007-12-05 2014-10-20 Чугаи Сейяку Кабусики Кайся Антитело против nr10 и его применение
EP4238993A3 (fr) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée
KR20160062207A (ko) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MA43918A (fr) 2015-04-14 2018-12-05 Chugai Pharmaceutical Co Ltd Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
TW202128222A (zh) 2019-11-20 2021-08-01 日商中外製藥股份有限公司 含有抗體之製劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482131C2 (ru) * 2004-05-10 2013-05-20 Эбдженомикс Кооператиф У.А. Антитела
RU2580017C2 (ru) * 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
RU2603097C2 (ru) * 2010-12-21 2016-11-20 Селексис Фармасьютикалс Корпорейшн Антитела к р-селектину и способы их применения и идентификации
US9944716B2 (en) 2011-02-25 2018-04-17 Regeneron Pharmaceuticals, Inc. ADAM6 mice
RU2582261C2 (ru) * 2011-02-25 2016-04-20 Редженерон Фармасьютикалс, Инк. Мыши adam6
US9932408B2 (en) 2011-02-25 2018-04-03 Regeneron Pharmaceuticals, Inc. ADAM6 mice
US10905109B2 (en) 2011-02-25 2021-02-02 Regeneren Pharmaceuticals, Inc. ADAM6 mice
US10072095B2 (en) 2011-02-25 2018-09-11 Regeneron Pharmaceuticals, Inc. ADAM6 mice
US11950578B2 (en) 2011-02-25 2024-04-09 Regeneron Pharmaceuticals, Inc. ADAM6 mice
US10577430B2 (en) 2011-02-25 2020-03-03 Regeneron Pharmaceuticals, Inc. ADAM6 mice
RU2722373C2 (ru) * 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
US10694725B2 (en) 2011-02-25 2020-06-30 Regeneron Pharmaceuticals, Inc. ADAM6 mice
US10905108B2 (en) 2011-02-25 2021-02-02 Regeneron Pharmaceuticals, Inc. ADAM6 mice
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US11612151B2 (en) 2011-12-20 2023-03-28 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US11617357B2 (en) 2011-12-20 2023-04-04 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US10561124B2 (en) 2011-12-20 2020-02-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US11666040B2 (en) 2012-06-12 2023-06-06 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RU2805176C1 (ru) * 2020-01-24 2023-10-11 Пфайзер Инк. Антитела против e-селектина, композиции и способы применения

Also Published As

Publication number Publication date
CA2149025A1 (fr) 1994-06-09
WO1994012215A1 (fr) 1994-06-09
AU5732794A (en) 1994-06-22
JPH08503617A (ja) 1996-04-23
FI952658A (fi) 1995-05-31
NO952160D0 (no) 1995-05-31
KR100371784B1 (ko) 2003-07-22
HUT71790A (en) 1996-02-28
HU9501564D0 (en) 1995-07-28
AU689090B2 (en) 1998-03-26
PL309249A1 (en) 1995-10-02
CZ140195A3 (en) 1996-06-12
EP0671951A1 (fr) 1995-09-20
FI952658A0 (fi) 1995-05-31
NO952160L (no) 1995-07-31
EP0671951A4 (fr) 1997-05-21

Similar Documents

Publication Publication Date Title
RU2151612C1 (ru) Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека
US6210671B1 (en) Humanized antibodies reactive with L-selectin
US6210670B1 (en) Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin
US6350861B1 (en) Antibodies with increased binding affinity
EP0753065B1 (fr) Anticorps contre la selectine e
EP0566647B1 (fr) Immunoglobulines humanisees ameliorees
EP1759709B1 (fr) Anticorps humanisés dirigés contre la molécule d'adhesion leucocytaire VLA-4
US20030185818A1 (en) Humanized antibody against cd18
EP0528767A1 (fr) Dérivés d'anticorps
US20130059337A1 (en) Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin
JPH04502408A (ja) ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン
AU3544589A (en) Il-2 receptor-specific chimeric antibodies
US7138116B2 (en) Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
WO1994012214A1 (fr) Anticorps humanises reagissant avec la cd-18
EP0606391B1 (fr) Inhibition du retrecissement vasculaire par l'utilisation d'anticorps anti-padgem
AU718463B2 (en) Inhibitor of lymphocyte activation
WO1995015181A1 (fr) Therapie de reperfusin comprenant l'utilisation d'anticorps diriges contre la l-selectine
WO1993001289A1 (fr) Anticorps humanises de recepteurs d'interleukine-2
JP2001510027A (ja) Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20041201